Pay in 4 interest-free payments of $5.84 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Some patients achieved a loss of an average of 15% of their body weight over 68 weeks, a result significantly higher than that achieved with other diabetes medications
Anderson, E.J
The most decisive weight-management comparison came later
It should also be noted that, from a methodological perspective, the model used (Cox with stratification by cardiovascular risk class of the trials, i.e., SURPASS-4: high risk, and all others: low risk) requires various assumptions, including the homogeneity of the relative effect of tirzepatide treatment on MACE regardless of the baseline cardiovascular risk level of the patients
0.5 ml syringe (50 units total): Marked in 1-unit increments
US$ 26.63
US$ 27.43
US$ 27.77
US$ 23.98
